Although the resistance to anti-IDH1/2 drugs was observed in cholangiocarcinoma and could represent an obstacle to the long-term treatment of patients with IDH inhibitors, this problem may be overcome by the use of dual inhibitors (targeting both IDH1 and IDH2), which are currently under evaluation. The gene discussed is IDH2; the disease is cholangiocarcinoma.